Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Advocates claim Gilead and others unfairly limited competition for HIV combination pills.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
Researchers at George Washington University take a look.
Participants entered the study taking tenofovir disoproxil fumarate, and some were switched to a regimen including tenofovir alafenamide.
The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.
That’s according to a study of 55 HIV-positive people with end-stage kidney failure.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.
This is according to a French study looking at discontinuations of Tivicay compared with Vitekta and Isentress.
That’s compared with HIV-negative men.
A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.